{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:21Z","timestamp":1792788381220,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372529"],"award-info":[{"award-number":["82372529"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32100643"],"award-info":[{"award-number":["32100643"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Foundation of State Key laboratory of Trauma and Chemical Poisoning","award":["2024K003"],"award-info":[{"award-number":["2024K003"]}]},{"name":"Major scientific and Technological Projects of Yunnan Province","award":["202502AA310012"],"award-info":[{"award-number":["202502AA310012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04772-x","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:27:40Z","timestamp":1763404060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mesenchymal stem cells combined with IFN-\u03b3 treatment versus mesenchymal stem cells monotherapy: safety and efficacy over five years extension follow-up"],"prefix":"10.1186","volume":"16","author":[{"given":"Yi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Guo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-2210","authenticated-orcid":false,"given":"Xiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"23","key":"4772_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB Mcinnes","year":"2011","unstructured":"Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205\u201319.","journal-title":"N Engl J Med"},{"key":"4772_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ebiom.2019.11.024","volume":"50","author":"X Bi","year":"2019","unstructured":"Bi X, Guo XH, Mo BY, et al. LncRNA picsar promotes cell proliferation, migration and invasion of fibroblast-like synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis. EBioMedicine. 2019;50:408\u201320.","journal-title":"EBioMedicine"},{"issue":"10","key":"4772_CR3","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1172\/JCI97965","volume":"128","author":"Y Zou","year":"2018","unstructured":"Zou Y, Xu S, Xiao Y, et al. Long noncoding RNA LERFS negatively regulates rheumatoid synovial aggression and proliferation. J Clin Invest. 2018;128(10):4510\u201324.","journal-title":"J Clin Invest"},{"key":"4772_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070856","volume":"384","author":"P Brown","year":"2024","unstructured":"Brown P, Pratt AG, Hyrich KL. Therapeutic advances in rheumatoid arthritis. BMJ. 2024;384:e070856.","journal-title":"BMJ"},{"issue":"1","key":"4772_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.arcmed.2020.08.006","volume":"52","author":"DE Rodriguez-Fuentes","year":"2021","unstructured":"Rodriguez-Fuentes DE, Fernandez-Garza LE, Samia-Meza JA, et al. Mesenchymal stem cells current clinical applications: a systematic review. Arch Med Res. 2021;52(1):93\u2013101.","journal-title":"Arch Med Res"},{"issue":"1","key":"4772_CR6","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Chiu SM, Motan DA, et al. Mesenchymal stem cells and immunomodulation current status and future prospects. Cell Death Dis. 2016;7(1):e2062.","journal-title":"Cell Death Dis"},{"issue":"3","key":"4772_CR7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","volume":"10","author":"D Wang","year":"2018","unstructured":"Wang D, Zhang H, Liang J, et al. A long-term follow-up study of allogeneic mesenchymal stem\/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Reports. 2018;10(3):933\u201341.","journal-title":"Stem Cell Reports"},{"issue":"3","key":"4772_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102755","volume":"20","author":"D Farge","year":"2021","unstructured":"Farge D, Loisel S, Lansiaux P, et al. Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmun Rev. 2021;20(3):102755.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"4772_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MOT.0000000000000158","volume":"20","author":"M Introna","year":"2015","unstructured":"Introna M, Rambaldi A. Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles. Curr Opin Organ Transplant. 2015;20(1):72\u20138.","journal-title":"Curr Opin Organ Transplant"},{"issue":"7","key":"4772_CR10","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/ard.2010.141804","volume":"70","author":"D Wang","year":"2011","unstructured":"Wang D, Zhang H, Cao M, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70(7):1285\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"4772_CR11","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1182\/blood-2011-11-391144","volume":"120","author":"J Xu","year":"2012","unstructured":"Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood. 2012;120(15):3142\u201351.","journal-title":"Blood"},{"issue":"1","key":"4772_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-018-1541-4","volume":"16","author":"Y Yang","year":"2018","unstructured":"Yang Y, He X, Zhao R, et al. Serum IFN-gamma levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis. J Translational Med. 2018;16(1):165.","journal-title":"J Translational Med"},{"issue":"10","key":"4772_CR13","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1136\/annrheumdis-2020-217798","volume":"79","author":"X He","year":"2020","unstructured":"He X, Yang Y, Yao M, et al. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. Ann Rheumatic Dis. 2020;79(10):1298\u2013304.","journal-title":"Ann Rheumatic Dis"},{"issue":"5 Suppl 101","key":"4772_CR14","first-page":"S40","volume":"34","author":"PL Van Riel","year":"2016","unstructured":"Van Riel PL, Renskers L. The disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S40-4.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"4772_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, et al. American college of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4772_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","volume":"74","author":"MH Buch","year":"2015","unstructured":"Buch MH, Silva-Fernandez L, Carmona L, et al. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis. 2015;74(6):963\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4772_CR17","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.1780331001","volume":"33","author":"DT Felson","year":"1990","unstructured":"Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990;33(10):1449\u201361.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4772_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1402-5","volume":"17","author":"F Ibrahim","year":"2016","unstructured":"Ibrahim F, Tom BD, Scott DL, et al. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. Trials. 2016;17(1):272.","journal-title":"Trials"},{"issue":"9","key":"4772_CR19","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287\u201393.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4772_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in Tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4772_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","volume":"59","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Genovese MC, Lin Y, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years\u2019 follow-up. Rheumatol. 2020;59(2):292\u2013302.","journal-title":"Rheumatol"},{"issue":"11","key":"4772_CR22","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/ard-2023-225473","volume":"83","author":"E Feist","year":"2024","unstructured":"Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Ann Rheum Dis. 2024;83(11):1454\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4772_CR23","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF Van Vollenhoven","year":"2013","unstructured":"Van Vollenhoven RF, Emery P, Bingham CO 3. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502., et al.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4772_CR24","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10067-009-1233-9","volume":"28","author":"A Wiens","year":"2009","unstructured":"Wiens A, Correr CJ, Venson R, et al. A meta-analysis of the efficacy and safety of using Infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol. 2009;28(12):1365\u201373.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4772_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2174\/1574888X13666180220141114","volume":"13","author":"F Huang","year":"2018","unstructured":"Huang F, Liu ZM, Zheng SG. Updates on GMSCs treatment for autoimmune diseases. Curr Stem Cell Res Ther. 2018;13(5):345\u20139.","journal-title":"Curr Stem Cell Res Ther"},{"key":"4772_CR26","doi-asserted-by":"publisher","first-page":"963689723116425","DOI":"10.1177\/09636897231164251","volume":"32","author":"F Chen","year":"2023","unstructured":"Chen F, Chen N, Xia C, et al. Mesenchymal stem cell therapy in kidney diseases: potential and challenges. Cell Transplant. 2023;32:9636897231164251.","journal-title":"Cell Transplant"},{"issue":"5","key":"4772_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/scd.2016.0207","volume":"26","author":"L Chow","year":"2017","unstructured":"Chow L, Johnson V, Coy J, et al. Mechanisms of immune suppression utilized by canine adipose and bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2017;26(5):374\u201389.","journal-title":"Stem Cells Dev"},{"issue":"1","key":"4772_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01122-3","volume":"13","author":"Q Huai","year":"2023","unstructured":"Huai Q, Zhu C, Zhang X, et al. Mesenchymal stromal\/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications. Cell Biosci. 2023;13(1):162.","journal-title":"Cell Biosci"},{"issue":"2","key":"4772_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cellimm.2008.04.009","volume":"251","author":"R Ramasamy","year":"2008","unstructured":"Ramasamy R, Tong CK, Seow HF, et al. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251(2):131\u20136.","journal-title":"Cell Immunol"},{"key":"4772_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1341321","volume":"15","author":"N Mena-Vazquez","year":"2024","unstructured":"Mena-Vazquez N, Redondo-Rodriguez R, Rojas-Gimenez M, et al. Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study. Front Immunol. 2024;15:1341321.","journal-title":"Front Immunol"},{"issue":"1","key":"4772_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-024-00431-5","volume":"8","author":"L Jin","year":"2024","unstructured":"Jin L, Gan J, Li X, et al. Rheumatoid arthritis and COVID-19 outcomes: a systematic review and meta-analysis. BMC Rheumatol. 2024;8(1):61.","journal-title":"BMC Rheumatol"},{"issue":"6","key":"4772_CR32","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s10067-020-05004-8","volume":"39","author":"LR Harrold","year":"2020","unstructured":"Harrold LR, Shan Y, Rebello S, et al. Prevalence of Sjogren\u2019s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry. Clin Rheumatol. 2020;39(6):1899\u2013905.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"4772_CR33","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1080\/14397595.2019.1682795","volume":"30","author":"H Kondo","year":"2020","unstructured":"Kondo H, Watanabe R, Okazaki S, et al. Coexistence of rheumatoid arthritis and systemic lupus erythematosus is still rare in the biologic era: report of seven cases and literature review. Mod Rheumatol. 2020;30(6):1082\u20133.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"4772_CR34","first-page":"79","volume":"58","author":"GW Cannon","year":"2008","unstructured":"Cannon GW, Pincus SH, Emkey RD, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis 1989. Arthr Rheum. 2008;58(2):79\u201388.","journal-title":"Arthr Rheum"},{"issue":"1","key":"4772_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/art.1780400110","volume":"40","author":"EM Veys","year":"1997","unstructured":"Veys EM, Menkes CJ, Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1997;40(1):62\u20138.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4772_CR36","first-page":"836","volume":"36","author":"C Yu","year":"2018","unstructured":"Yu C, Li M, Duan X, et al. Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2018;36(5):836\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"4772_CR37","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4772_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/14397595.2017.1294302","volume":"27","author":"A Nakajima","year":"2017","unstructured":"Nakajima A, Aoki Y, Terayama K, et al. Health assessment questionnaire-disability index (HAQ-DI) score at the start of biological disease-modifying antirheumatic drug (bDMARD) therapy is associated with radiographic progression of large joint damage in patients with rheumatoid arthritis. Mod Rheumatol. 2017;27(6):967\u201372.","journal-title":"Mod Rheumatol"}],"container-title":["Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04772-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04772-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04772-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:27:41Z","timestamp":1763404061000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04772-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4772"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04772-x","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Daping Hospital, Army Military Medical University of the Chinese People\u2019s Liberation Army (Approval ID: YIYANLUNSHEN (2016) NO. 007) on March 6, 2016, under the title \u201cSafety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis (RA)\u201d and (Approval ID: YIYANLUNSHEN (2016) NO.016) on September 25, 2016, under the title \u201cSafety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells combined with recombinant human gamma interferon (IFN-\u03b3) in the treatment of Rheumatoid Arthritis (RA)\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All enrolled patients have provided written informed consent for participation in the study and the use of samples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"642"}}